4D Molecular Therapeutics Inc (FDMT) — Cash Flow Quality Index

Latest as of December 2025: 1.47x

4D Molecular Therapeutics Inc (FDMT) has a Cash Flow Quality Index of 1.47x as of December 2025. Operating cash flow of $28.55 Million exceeds net income of $19.40 Million, indicating high earnings quality where cash backs reported profits. Explore investment intensity of 4D Molecular Therapeutics Inc to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

1.47x

Operating CF / Net Income

Operating Cash Flow

$28.55 Million

USD

Net Income

$19.40 Million

USD

Data as of

Dec 2025

Most recent filing

Annual Cash Flow Quality Index for 4D Molecular Therapeutics Inc (None–None)

Year-by-year earnings quality comparison for 4D Molecular Therapeutics Inc. For live market cap and the full company financial profile, see how much is 4D Molecular Therapeutics Inc worth.

Year	Quality Index	Operating CF (USD)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.